These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3425313)

  • 1. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
    Pedersen SS; Jensen T; Høiby N; Koch C; Flensborg EW
    Acta Paediatr Scand; 1987 Nov; 76(6):955-61. PubMed ID: 3425313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
    Szaff M; Høiby N; Flensborg EW
    Acta Paediatr Scand; 1983 Sep; 72(5):651-7. PubMed ID: 6637463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of early Pseudomonas aeruginosa infection.
    Høiby N; Frederiksen B; Pressler T
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():49-54. PubMed ID: 16023416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled tobramycin (TOBI).
    Bonsignore CL
    Pediatr Nurs; 1998; 24(3):258-9. PubMed ID: 9987427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
    Parry MF; Neu HC
    J Infect Dis; 1976 Aug; 134 Suppl():S194-7. PubMed ID: 823276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis.
    Hodson ME; Wingfield HJ; Batten JC
    Br J Dis Chest; 1983 Jan; 77(1):71-7. PubMed ID: 6407508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
    Ratjen F; Döring G; Nikolaizik WH
    Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Crozier DN; Khan SR
    J Infect Dis; 1976 Aug; 134 Suppl():S187-90. PubMed ID: 823275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
    Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N
    Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.
    Martin AJ; Smalley CA; George RH; Healing DE; Anderson CM
    Arch Dis Child; 1980 Aug; 55(8):604-7. PubMed ID: 7436516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.
    Hurley M; Smyth A
    Ther Adv Respir Dis; 2012 Dec; 6(6):363-73. PubMed ID: 22968160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and treatment of cystic fibrosis patients with lung infections caused by Pseudomonas (Burkholderia) cepacia and multiresistant Pseudomonas aeruginosa.
    Høiby N
    Neth J Med; 1995 Jun; 46(6):280-7. PubMed ID: 7643943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
    Paporisz U; Posselt HG; Wönne R; Ristow W; Röser D; Knothe H; Bender SW
    Eur J Pediatr; 1979 Apr; 130(4):259-69. PubMed ID: 436850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Woodward TC; Brown R; Sacco P; Zhang J
    J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
    Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.